SEC Form 4 · accession 0001144204-18-032714
Cyclacel Pharmaceuticals, Inc. · CYCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David C Uprichard
Director
Period of report
May 31, 2018
Accepted (ET)
Jun 4, 2018 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130166
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.42 | May 31, 2018 | A | 8,576 | A | May 31, 2019 | May 31, 2028 | Common Stock | 8,576 | 8,576 | D |
Explanation of responses
- F1These options were granted to Dr. U'Prichard for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.